AKRO实时信号 | 通过Getagraph.com最大化利润

购买 93968 min ago

@ $22.13

发出时间: 15 Feb 2024 @ 03:43

回报率: -6.19%

上一信号: Feb 14 - 04:49

上一信号: 出售

回报率: 7.64 %

Live Chart Being Loaded With Signals

Commentary (20 Apr 2024 @ 04:00):

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health...

Stats
今日成交量	769 121
平均成交量	1.39M
市值	1.43B
EPS	$0 ( 2024-03-15 )
下一个收益日期	( $-0.860 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.18
ATR14	$0.0320 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Young Jonathan	Sell	4 600	Common Stock
2024-04-01	Young Jonathan	Sell	400	Common Stoek
2024-03-13	Yale Catriona	Sell	723	Common Stock
2024-03-13	White William Richard	Sell	724	Common Stock
2024-03-13	Cheng Andrew	Sell	1 969	Common Stock

INSIDER POWER
52.14
Last 100 transactions
Buy: 2 061 541 \| Sell: 638 251

音量相关性

長: 0.26 (neutral)

短: -0.47 (neutral)

Signal:(33.533) Neutral

Akero Therapeutics Inc 相关性

10 最正相关
AZYO	0.936
GNSS	0.933
VRAR	0.929
UBOH	0.929
NVCT	0.922
CULL	0.919
VERA	0.919
JRJC	0.918
EDSA	0.917
BRQS	0.91

10 最负相关
RXDX	-0.979
FLMN	-0.968
ZYNE	-0.962
RESN	-0.962
ZGNX	-0.959
CYT	-0.958
ADMS	-0.946
RETA	-0.946
ORTX	-0.938
XLRN	-0.931

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Akero Therapeutics Inc 相关性 - 货币/商品

0.86
( strong )

0.79
( moderate )

0.00
( neutral )

0.82
( strong )

0.05
( neutral )

0.35
( neutral )

Akero Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-29 000.00 (0.00 %)
EPS:	$-2.89

Q4	2023
营收:	$284 000
毛利润:	$282 000 (99.30 %)
EPS:	$-0.990

Q3	2023
营收:	$0
毛利润:	$-5 000.00 (0.00 %)
EPS:	$-0.710

Q2	2023
营收:	$0
毛利润:	$-69 000.00 (0.00 %)
EPS:	$-0.600

Financial Reports:

No articles found.

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.